Danaher to acquire Aldevron in deal valued at $9.6B

By Will Morton, The Science Advisory Board contributing writer

June 17, 2021 -- Danaher announced it has signed a deal to buy DNA and messenger RNA (mRNA) manufacturer Aldevron for approximately $9.6 billion. Aldevron will operate as a standalone company in Danaher's Life Sciences business segment and is expected to boost Danaher's activities in genomic medicine.

Aldevron manufactures plasmid DNA, mRNA, and proteins, and serves biotechnology and pharmaceutical customers involved in research, clinical, and commercial applications. The privately held company is based in Fargo, ND, and employs approximately 600 people.

Rainer Blair, Danaher president and CEO, said the deal is expected to boost Danaher's activities in genomic medicine and improve the company's ability to support customers developing vaccines and other therapies, such as in cell and gene therapy.

Danaher said it expects to finance the purchase using cash on hand and proceeds from the issuance of commercial paper.

In 2020, Danaher bought GE's biopharma business.

The Aldevron purchase is subject to customary conditions, including receipt of applicable regulatory approvals, according to the company. Danaher operates more than 20 companies and a team of about 69,000 associates worldwide.


Copyright © 2021 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.